Funding
$200M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional clinical trial sites are limited to physical locations, reaching less than 10% of eligible patients and requiring participants to travel long distances, which hampers enrollment, diversity, and retention.
Solution
Science 37 operates the industry’s only FDA‑inspected Direct‑to‑Patient (DTP) site, delivering the full suite of clinical trial services directly to participants’ homes across all 50 U.S. states. A single FDA 1572 and central IRB streamline regulatory oversight, while licensed research‑grade nurses conduct protocol‑specific assessments, IMP handling, and sample collection on‑site. Remote investigators monitor safety and data in real time, ensuring the same quality standards as a traditional brick‑and‑mortar site. Nationwide logistics—including home delivery of study kits and investigational products—expand reach to 100 % of the target population, accelerate first‑patient‑in timelines, and improve enrollment speed and retention. The model consistently contributes 20–30 % of total study enrollment as a single site and achieves completion rates around 86 %.
Target Audience
Primary customers are pharmaceutical and biotech sponsors seeking to accelerate enrollment, improve diversity, and reduce patient burden for Phase I‑IV interventional and observational trials.
Features
- FDA‑inspected DTP site with No Action Indicated (NAI) classification for multiple Phase 3 trials
- 50‑state medical licensure and a single FDA 1572/IRB submission to simplify start‑up
- Research‑grade nursing team (150+ nurses) certified in GCP, HSR, IATA, and study‑specific procedures
- Home delivery of investigational medicinal products and study kits with chain‑of‑custody tracking
- Remote investigator oversight and real‑time data capture mirroring traditional site operations
- Proven enrollment performance: 86 % visit completion, 13 000+ in‑home visits, and up to 49 % of total study enrollment
- Therapeutic‑area agnostic capability covering chronic diseases, rare disorders, pediatrics, and oncology